ASH 2014 Conference Review.
By Emad Al Muti, Analyst
11 December 2014
I am an Analyst in the diseases team at Datamonitor Healthcare. I have a Doctoral degree in Pharmacy, and a Master’s d...
Read full bio
Datamonitor Healthcare attended the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place between 6 December and 9 December 2014, in San Francisco, California. Datamonitor Healthcare has identified the following key highlights from the meeting:
- Data from Phase I and Phase II trials investigating several therapies based on chimeric antigen receptor T-cells (CAR-Ts) indicated promising efficacy for this class of therapies in the treatment of various B-cell malignancies, including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL). Among the key CAR-T therapies discussed were Novartis’s Phase II CTL019, Juno Therapeutics’ 19-28z CAR-T (JCAR015) technology, and Kite Pharma’s new anti-CD19 CAR-T therapy.
- Monoclonal antibodies (MAbs) continue to advance in pipeline development for multiple myeloma (MM). Early clinical phase data highlighted noteworthy responses achieved by adding the Phase III daratumumab (HuMax-CD38; Janssen/Genmab) or elotuzumab (HuLuc63; Bristol-Myers Squibb/AbbVie) to currently existing backbone therapy regimens during the treatment of newly diagnosed and relapsed/refractory MM patients. Phase I data for Sanofi’s CD38-targeting MAb SAR650984 also highlighted a potential role for this drug in the treatment of MM.
Posted in Oncology.